RAND's divisions conduct research on a uniquely broad front for clients around the globe.
Most relevant regions
Research
Jan 1, 2006
A 66-year-old man with hypertension, hyperlipidemia, and benign prostatic hyperplasia presented for evaluation of an elevated PSA level of 6.2 ng/ml.
Cause-specific mortality rates among men with prostate cancer that suggest early diagnosis and treatment for localized tumors may improve survival.
Jan 1, 2005
Men with lower pretreatment quality-of-life measures may be at increased risk of fatigue after prostate cancer treatment
Economically disadvantaged men with prostate cancer report worse mental health than people with other chronic diseases.
Assessing bowel function (BF) in prostate cancer can help determine therapeutic trade-offs.
To describe and compare health related quality of life (HRQOL) among Hispanic, African-American, and Caucasian men with localized prostate cancer.
The UCSF-CAPRA score is a straightforward yet powerful preoperative risk assessment tool.
Being partnered confers benefits in survival for patients with prostate cancer, yet little is known of the impact of relationship status on HRQOL.
This work provides new insights into HRQOL over time in a low-income, multiethnic group of patients with prostate cancer.
To validate an Italian version of the University of California-Los Angeles Prostate Cancer Index (UCLA-PCI).
The authors found no socioeconomic or demographic disparities in the receipt of postprostatectomy radiotherapy.
Within a framework of quality assessment, primary treatment choice constitutes an indicator of quality of care.